Video, enVista® IOL in Oculocutaneous Albinism Patient

In this educational video, Anil Shivaram, MD of Claremont Eye Associates implants the enVista® IOL from Bausch + Lomb in a patient with type 1 oculocutaneous albinism utilizing the Stellaris® Vision Enhancement System and Storz CapsuleGuard IA handpiece.

Related Videos

Related Content

Advertisement

December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Published: December 19th 2024 | Updated: December 19th 2024

Study validates long-term efficacy of MicroPulse TLT for glaucoma management

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

December 18th 2024

Viridian announces topline data from THRIVE-2 phase 3 clinical trial of veligrotug for treatment of thyroid eye disease

December 18th 2024

Aurion Biotech announces topline results from Phase 1/2 trial of AURN001 for corneal edema

Related Content

Advertisement

December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Published: December 19th 2024 | Updated: December 19th 2024

Study validates long-term efficacy of MicroPulse TLT for glaucoma management

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

December 18th 2024

Viridian announces topline data from THRIVE-2 phase 3 clinical trial of veligrotug for treatment of thyroid eye disease

December 18th 2024

Aurion Biotech announces topline results from Phase 1/2 trial of AURN001 for corneal edema